Physiologically‐Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID‐19
Open Access
- 27 January 2021
- journal article
- research article
- Published by Wiley in Cancer Cell
- Vol. 109 (4), 1116-1124
- https://doi.org/10.1002/cpt.2176
Abstract
Severe COVID‐19 disease including multisystem inflammatory syndrome (MIS‐C) have been reported in children. This report summarizes development of remdesivir physiologically‐based pharmacokinetic (PBPK) model that accurately describes observed adult remdesivir and metabolites exposure and predicts pediatric remdesivir and metabolites exposure. Adult PBPK model was applied to predict pediatric remdesivir and metabolites steady‐state exposures using the Pediatric Population Model in SimCYP and incorporated the relevant physiologic and mechanistic information. Model development was based on adult Phase 1 exposure data in healthy volunteers who were administered a 200 mg loading dose of remdesivir IV over 0.5 hr on Day 1, then 100 mg daily maintenance doses of remdesivir intravenous (IV) over 0.5 hr starting on Day 2 and continuing through Days 5 or 10. Simulations indicated that use of the adult therapeutic remdesivir dosage regimen (200 mg loading dose on Day 1 then 100 mg daily maintenance dose starting on Day 2) in pediatric patients ≥40 kg and a weight‐based remdesivir dosage regimen (5 mg/kg loading dose on Day 1 then 2.5 mg/kg daily maintenance dose starting on Day 2) in pediatric patients weighing 2.5 ‐ <40 kg is predicted to maintain therapeutic exposures of remdesivir and its metabolites. The comprehensive PBPK model described in this report supported remdesivir dosing in planned pediatric clinical studies and dosing in the emergency use authorization and pediatric compassionate use programs that were initiated to support RDV as a treatment option during the pandemic.Keywords
This publication has 33 references indexed in Scilit:
- Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With ConfidenceCancer Cell, 2017
- Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in InfantsDrug Metabolism and Disposition, 2016
- A Physiologically Based Pharmacokinetic Model to Describe Artemether Pharmacokinetics in Adult and Pediatric PatientsJournal of Pharmaceutical Sciences, 2016
- Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in ChildrenCPT: Pharmacometrics & Systems Pharmacology, 2016
- Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal OntogenyDrug Metabolism and Disposition, 2016
- The Simcyp Population Based Simulator: Architecture, Implementation, and Quality AssuranceIn Silico Pharmacology, 2013
- Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosidesBioorganic & Medicinal Chemistry Letters, 2012
- First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug developmentJournal of Pharmacokinetics and Pharmacodynamics, 2012
- Knowledge‐driven approaches for the guidance of first‐in‐children dosingPediatric Anesthesia, 2010
- Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and ChildrenClinical Pharmacokinetics, 2006